Expand AKRO Menu
AKRO MENU

AKRO Latest Press Releases

-- April 16, 2024 --

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Akero Therapeutics, Inc. - AKRO Globe Newswire 2:54 PM

-- April 8, 2024 --

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Akero Therapeutics, Inc. - AKRO Globe Newswire 3:09 PM

-- April 6, 2024 --

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Akero Therapeutics, Inc. - AKRO PRNewswire 1:04 AM

-- April 4, 2024 --

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Akero Therapeutics, Inc. - AKRO PRNewswire 7:25 PM

-- April 2, 2024 --

Ademi LLP Investigates Claims of Securities Fraud against Akero Therapeutics, Inc. PRNewswire 6:05 PM

-- March 28, 2024 --

Akero Therapeutics Class Action Investigation: Johnson Fistel has Commenced an Investigation on Behalf of Akero Therapeutics Shareholders Globe Newswire 4:30 PM

-- March 20, 2024 --

AKRO Investor Notice: Abraham, Fruchter & Twersky, LLP Investigating Claims on Behalf of Investors of Akero Therapeutics (NASDAQ:AKRO) Globe Newswire 12:58 PM

-- March 15, 2024 --

Akero Therapeutics Class Action Investigation: Johnson Fistel has Commenced an Investigation on Behalf of Shareholders Globe Newswire 10:25 AM

-- March 8, 2024 --

Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares Globe Newswire 4:02 PM

-- March 7, 2024 --

Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology Globe Newswire 4:01 PM

-- March 5, 2024 --

Akero Therapeutics Announces Pricing of Public Offering of Common Stock | AKRO Stock News EDM Media 10:36 PM
Akero Therapeutics Announces Pricing of Public Offering of Common Stock Globe Newswire 9:13 PM

-- March 4, 2024 --

Akero Therapeutics Announces Proposed Public Offering of Common Stock Globe Newswire 4:21 PM
Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study Globe Newswire 6:00 AM

-- February 29, 2024 --

Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study Investigating Efruxifermin in Patients with Pre-Cirrhotic MASH Globe Newswire 8:00 AM
Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Globe Newswire 7:00 AM

-- February 26, 2024 --

Akero Therapeutics Class Action Investigation: Johnson Fistel has Commenced an Investigation on Behalf of Akero Therapeutics Shareholders Globe Newswire 9:24 AM

-- January 3, 2024 --

Akero Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference Globe Newswire 8:15 AM

-- December 18, 2023 --

Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program Globe Newswire 7:00 AM